<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
<head>
	<meta http-equiv="Content-Type" content="text/html; charset=UTF-8">
	<title>Parasympathotropic drugs: parasypathomimetics (cholinergics) and</title>
	<meta name='Generator' content='Zim 0.73.1'>
	<style type='text/css'>
		a          { text-decoration: none      }
		a:hover    { text-decoration: underline }
		a:active   { text-decoration: underline }
		strike     { color: grey                }
		u          { text-decoration: none;
					 background-color: yellow   }
		tt         { color: #2e3436;            }
		pre        { color: #2e3436;
					 margin-left: 20px          }
		h1         { text-decoration: underline;
					 color: #4e9a06; margin-bottom: 0 }
		h2         { color: #4e9a06; margin-bottom: 0 }
		h3         { color: #4e9a06; margin-bottom: 0 }
		h4         { color: #4e9a06; margin-bottom: 0 }
		h5         { color: #4e9a06; margin-bottom: 0 }
		p          { margin-top: 0              }
		span.zim-tag {
			color: #ce5c00;
		}
		div.zim-object {
			border-style:solid;
			border-width:1px;
		}
		.checked-box {list-style-image: url(data:image/png;base64,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)}
		.xchecked-box {list-style-image: url(data:image/png;base64,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)}
		.unchecked-box {list-style-image: url(data:image/png;base64,iVBORw0KGgoAAAANSUhEUgAAABgAAAAYCAYAAADgdz34AAAAAXNSR0IArs4c6QAAAAZiS0dEAP8A/wD/oL2nkwAAAAlwSFlzAAANOgAADMQBiN+4gQAAAAd0SU1FB9gKGQ8qAt8h3m8AAAAZdEVYdENvbW1lbnQAQ3JlYXRlZCB3aXRoIEdJTVBXgQ4XAAAA60lEQVRIx+2VsQqDMBRF70sCLg5OLoKgjk7+lJ/hh+STXBwcnRz8ArMEkrxOFktbaC3tULzTg5e8k5vADXDq70VbobXmvu/hvQczg4heHrJfXxQFuq67blZbMc8zpmlCXddIkgTOuZcBUko45zCOI6y1Nz2xFSEEZFmGOI7fGg4A3nsQEZqmuXOu9jallACAtm3fvmutNaIoAjM/dkBECCF89KCbk4eAb+kEnIAT8EsAM0OIz3hSyrssUvss8t5fg+uIrLXPs0gIgWVZYIyBUurQyYdheO4gz3NUVQVjDNZ1PfSjpWmKsixvehfB9GBZ3NndrgAAAABJRU5ErkJggg==)}
		.migrated-box {list-style-image: url(data:image/png;base64,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)}
		ul {list-style-image: none}
		/* ul rule needed to reset style for sub-bullets */
	</style>
</head>
<body>

<!-- Header -->
<div class='header'>
	[ <a href='./Pharmacognosy.html'>Prev</a> ]

	[ <span class='insen'>Index</span> ]

	[ <a href='..\23.html'>Next</a> ]
</div>

<hr />

<!-- Wiki content -->

<div class='pages'>
	<div class='heading'>
	<h1>Parasympathotropic drugs: parasypathomimetics (cholinergics) and <a name='22:Pharmacology'></a></h1>
	</div>

	<div class='content'>
	
<h1>parasypatholytics (cholinolytics)</h1>

<br>

<p>
<img src="./Pharmacology/pasted_image004.png">
</p>

<h1>Overview</h1>

<p>
→ drugs affeting ANS are divided into two groups according to the type of neuron they affect<br>
<ul style='padding-left: 30pt'>
<li>Cholinergic drugs
<ul>
<li>act on receptor that are activated by acetylcholine (ACh)</li>
</ul>
</li>
<li>Adrenergic drugs
<ul>
<li>act on receptor stimulated by norepinephrine or epinephrine</li>
</ul></li>
</ul>
→ both stimulating/blocking receptors of the ANS
</p>

<h1>THE CHOLINERGIC NEURON</h1>

<p>
→ preganglionic fibers terminated in adrenal medulla<br>
<ul style='padding-left: 30pt'>
<li>autonomic ganglia (para and sympa) + the postganglionic fibers of the para division
<ul>
<li>use ACh as a neurotransmitter</li>
</ul>
</li>
<li>also the postganglionic sympathetic division of sweat glands use ACh</li>
</ul>
→ cholinergic neurons innervate<br>
<ul style='padding-left: 30pt'>
<li>muscles of somatic system + important role in CNS</li>
</ul>
</p>

<h1>Neurotranmission at cholinergic neurons</h1>

<p>
→ six sequential steps<br>
1.sythesis<br>
2.storage<br>
3.release<br>
4.binding of the ACh to a receptor<br>
5.degradation of the neurotransmitter in the synaptic cleft<br>
6.recycling of choline and acetate.
</p>

<p>
→ <img src="./Pharmacology/pasted_image.png">
</p>

<br>

<h1>Synthesis of aceytlcholine</h1>

<p>
→ choline is transported from the extracellular fluid into cytoplasm of the cholinergic neuron into the cytoplasm<br>
<ul style='padding-left: 30pt'>
<li>by carrier system that contraposrts sodium and be inhibited by the drug hemicholinium</li>
</ul>
[<i>choline has a positive charge and thus cannot diffuse though the membrance.]</i><br>
→ uptake of the choline is the rate-limmiting step in ACh synthesis.<br>
→ Choline acetyl-tranferase catalyze the reaciton of choline with acetyl coenzyme<br>
<ul style='padding-left: 30pt'>
<li>A(CoA) to form ACh (ester) in the cytostol</li>
<li>acetyl coa derived from the mitochondria</li>
</ul>
</p>

<h1>Storage of acetycholine in vesicles.</h1>

<p>
→ ACh is packaged and stored into <br>
<ul style='padding-left: 30pt'>
<li>presynaptic vehicles
<ul>
<li>by an active transport process coupoled to the efflux of protons.</li>
</ul></li>
</ul>
→ they contain not only acetylcholine but also  ATP<br>
<ul style='padding-left: 30pt'>
<li>ATP=cotransmitter
<ul>
<li>↑ / ↓ the effect of the primary neurotransmitter</li>
</ul></li>
</ul>
</p>

<h1>Release of acetylcholine</h1>

<p>
→ after an action potetnial by voltage-sensitive sodium channel (nerve ending)<br>
<ul style='padding-left: 30pt'>
<li>arrives at voltage-sensitive calcium channel (presynaptic membrane)
<ul>
<li>causing an ↑ in the conc. of intracellular calclium 
<ul>
<li>↑ levels of calcium 
<ul>
<li>promotes fusion of synaptic vehicles
<ul>
<li>and release of their contants into the synaptic space.</li>
</ul></li>
</ul></li>
</ul></li>
</ul></li>
</ul>
→ the release can be blocked by botulinum toxin
</p>

<h1>Binding to the receptor</h1>

<p>
→ ACh released from the synaptic vesicles<br>
<ul style='padding-left: 30pt'>
<li>diffuses across the synaptic space 
<ul>
<li>binds to either 
<ul>
<li>of two postsynaptic receptors on the target cell</li>
<li>presynaptic receptor (in the membrane of the neuron that ACh released)</li>
<li>other targeted presynaptic receptors</li>
</ul></li>
</ul></li>
</ul>
→ postsynaptic receptors on the surface of the effector organ<br>
<ul style='padding-left: 30pt'>
<li>muscarinic</li>
<li>nicotinic</li>
</ul>
→ all this process leading to a biologic response<br>
<ul style='padding-left: 30pt'>
<li>initiation of a nerve impulses in postganglinoic fibers</li>
<li>activation of specific enezymes in effectors cells.
<ul>
<li>as  mediated by second-messagner molecules.</li>
</ul></li>
</ul>
</p>

<h1>Degradation of acetylcholine</h1>

<p>
→ <a href="./AChE.html" title="AChE" class="page">AChE</a> cleaves ACh <br>
<ul style='padding-left: 30pt'>
<li>to choline and acetate in the synaptic cleft</li>
</ul>
</p>

<h1>Recycling of choline</h1>

<p>
→ choline may be recaptured by a sodium-coupled<br>
<ul style='padding-left: 30pt'>
<li>high affinity uptake system 
<ul>
<li>which transport the molecule back into the neuron.</li>
</ul></li>
</ul>
→ acetylated into the ACh that is stored until is released by a subsequent aciton potential.<br>
<img src="./Pharmacology/pasted_image001.png">
</p>
<h1>CHOLINERGIC RECEPTORS (CHOLINOCEPTORS)</h1>

<p>
→ two families of cholinoreceptors <br>
<ul style='padding-left: 30pt'>
<li>muscarinic </li>
<li>nicotinic </li>
</ul>
→ distinguished from each other on the basis of their different affinities for agents that mimic the aciton of ACh<br>
<ul style='padding-left: 30pt'>
<li>cholinomimeteic agents</li>
<li>parasympathomimetics</li>
</ul>
</p>

<h1>Muscarinic receptors</h1>

<p>
→ G-protein-coupled receptors<br>
→ in addition of Ach binding<br>
<ul style='padding-left: 30pt'>
<li>also recognize muscarine (an alkaloid found in poisonous mush)</li>
</ul>
→ five sub-classes<br>
<ul style='padding-left: 30pt'>
<li>m1,m2,m3,m4,m5</li>
<li>M1,M2,M3 have been funcitonally characterized.</li>
</ul>
</p>

<h1>Location of muscarinic receptors</h1>

<p>
→ ganglia of the peripheral nervous system<br>
→ autonomic effector organs<br>
<ul style='padding-left: 30pt'>
<li>heart,smooth muscle,brain and exocrine glands</li>
</ul>
→ M1= gastric parietal cells<br>
→ M2= cardiac cells ,smooth muscle<br>
→ M3=blader,exocrine glands,smooth muscle.
</p>

<h1>Mechanism of acetylcholine siglan  transduction</h1>

<p>
→ different molecular mechanims<br>
→ M1 and M3 activated<br>
<ul style='padding-left: 30pt'>
<li>undergoes conformational changes
<ul>
<li>interact with G protein
<ul>
<li>which activates <i>phospholipace C1</i>
<ul>
<li>leads ot hydrolysis of <i>phosphatidylinostil-(4,5)-bisphosphate </i>
<ul>
<li>to yield <i>diacylglycerol(</i>activates protein kinase C)and<i> inositol (1,4,5)-triphosphate </i>   → (↑ intracellular Ca2+)</li>
</ul></li>
</ul></li>
</ul></li>
</ul></li>
</ul>
<div style='padding-left: 150pt'>
   [both are second-messangers]
</div>
<ul style='padding-left: 210pt'>
<li>this cation stimulate or inhibit enzymes,hyperpolarization,secretion,contranction</li>
</ul>
→ M2 subtype on the cardiac cells<br>
<ul style='padding-left: 30pt'>
<li>stimulates G protein 
<ul>
<li>inhibits adenylyl cyclase and increase K+ conductance</li>
</ul>
</li>
<li>heart responds with a decrease in rate and foce of contranction.</li>
</ul>
</p>

<h1>Muscarinic agonists and antagonists</h1>

<p>
→ piperizine<br>
<ul style='padding-left: 30pt'>
<li>tricylic anticholinergic drug has a greater selectively for inhibiting 
<ul>
<li>M1 muscarinic receptor[such as in the gastric muscosa]</li>
<li>also produce refelx tachycardia on rapid infunsion due to blockage of M2</li>
</ul></li>
</ul>
→ darifenacin<br>
<ul style='padding-left: 30pt'>
<li>competative muscarinic receptor antagonist
<ul>
<li>with greater affinity of M3 receptor than for the other receptors.</li>
</ul>
</li>
<li>drug is used for overactive baldder</li>
</ul>
</p>

<h1>Νicotinic receptors</h1>

<p>
→ in addition to binding ACh also recognize nicotine<br>
<ul style='padding-left: 30pt'>
<li>but slow weak affinity for muscarine</li>
</ul>
→ function as ligand-gated ion channel<br>
→ binding of Ach molecules elicts conformational changes that allows the entry of sodium ions<br>
<ul style='padding-left: 30pt'>
<li>depolarization of the effector cell</li>
</ul>
→ nicotine at low conc. stimulates the receptor<br>
<ul style='padding-left: 30pt'>
<li>at high conc. blocks the receptor</li>
</ul>
→ located<br>
<ul style='padding-left: 30pt'>
<li>CNS</li>
<li>adrenal medulla</li>
<li>autonomic ganglia</li>
<li>NMJ(neuromuscular junciton )</li>
<li><img src="./Pharmacology/pasted_image003.png"></li>
</ul>
</p>

<h1>DIRECT-ACTING CHOLINERGIC AGONIST</h1>

<p>
→ Cholinergic agonists<br>
<ul style='padding-left: 30pt'>
<li>also known as parasympathomimetics
<ul>
<li>mimic the effects of ACh
<ul>
<li>by directly binding to cholinoceptors</li>
</ul></li>
</ul></li>
</ul>
→ broadly classified into groups<br>
<ul style='padding-left: 30pt'>
<li><i>choline esters </i>(include ACh)</li>
<li><i>synthetic esters (carbachol and bethanechol) → and naturally occuring "pilocarpine"</i></li>
</ul>
→ all of the direct-acting cholinergic drugs<br>
<ul style='padding-left: 30pt'>
<li>have longer duration of aciton than Ach</li>
</ul>
→ bind to muscarinic receptor (sometimes reffered as muscarinic agents)<br>
→ show little specificity in their actions, which limits their clinical use
</p>

<h1>Acetylcholine</h1>

<p>
→ quaternary ammonium compound<br>
<ul style='padding-left: 30pt'>
<li>cannot penetrate membranes</li>
</ul>
→ although is a neurotransmitter of<br>
<ul style='padding-left: 30pt'>
<li>parasympathetic </li>
<li>somatic nerves</li>
<li>autonomic ganglia 
<ul>
<li>it lack  therapeutic importance because of its multiplicity
<ul>
<li>leading to diffuse effects
<ul>
<li>rapid inactivation by the cholinesterases</li>
</ul></li>
</ul></li>
</ul></li>
</ul>
→ ACh has both muscarinic and nicotinic activity
</p>

<p>
1.↓ HEART RATE AND CARDIAC OUTPUT<br>
→ mimic the effect of vagal stimulation<br>
e.g. // injeceted ACh produce a brief ↓ in cardiac rate and stroke volume as a result of a reduction in the rate of firing.<br>
<ol type="1" start="2">
<li>↓BLOOD PRESSURE</li>
</ol>
→ causes vasodilation and lower blood pressure (inderect)<br>
→ ACh3 activates M3 found on endotheliali cells lining the smooth muscle of blood vessels-<br>
<ul style='padding-left: 30pt'>
<li>resulting in production in nitric oxide from arginine.
<ul>
<li>NO diffuses to vasular smooth muscsle 
<ul>
<li>to stimulate protein kinase G production
<ul>
<li>leading to hyperpolarization and smooth muscsle relaxation/</li>
</ul></li>
</ul></li>
</ul></li>
</ul>
→ <i>Atropine →</i>blocks these muscarinic receptors and prevents ACh from producing vasodilation.<br>
3.OTHER ACTIONS<br>
→ in GIT<br>
<ul style='padding-left: 30pt'>
<li>↑ salivary secretion and stimulates intenstial secretions and motility</li>
<li>enchances bronchiolar secretion</li>
</ul>
→ in Genitourinary<br>
<ul style='padding-left: 30pt'>
<li>ACh ↑ the tone of the detrusor urinae muscle</li>
</ul>
</p>
<h1>Bethanechol</h1>

<p>
→ unsbustituted carbomoyl ester<br>
<ul style='padding-left: 30pt'>
<li>structually related to ACh
<ul>
<li>in which replaced by carbamatae and the cholin methylated</li>
</ul></li>
</ul>
→ it's not hydrolyzed by <a href="./AChE.html" title="AChE" class="page">AChE</a><br>
<ul style='padding-left: 30pt'>
<li>although is inactivated through hydrolysis by other esterases</li>
</ul>
→ lacks nicotinic actions  (due to the addition of the methyl group)<br>
<ul style='padding-left: 30pt'>
<li>but does have STRONG muscarinic activity</li>
</ul>
→ major aciton on smooth muscularate of the bladder and GI tract.<br>
→ about 1 hour of duration<br>
1.ACTIONS<br>
→ directly stimulates muscsarinic receptors <br>
<ul style='padding-left: 30pt'>
<li>↑ intestinal motility and tone</li>
<li>stimulates the detrusor muscsle of the bladder</li>
<li>trigone and sphincter are relaxed</li>
</ul>
→ these actions<br>
<ul style='padding-left: 30pt'>
<li>↑ voiding pressure and ↓ bladder capacity to cause explusion of urine</li>
</ul>
2.THERAPEUTIC APPLICATION<br>
→ urologic treatment<br>
<ul style='padding-left: 30pt'>
<li>stimulate the atonic bladder
<ul>
<li>particulary in postpartum or postperative nonobstructive urinary retention.</li>
</ul></li>
</ul>
→ may also used to treat neurogenic atony as well as megacolon.<br>
3.ADVERSE EFFECT<br>
→ causes the effects of generalized cholinergic stimulation<br>
→ sweating,salivation,flushing,↓ blood pressure , nausea,abdominal pain,
</p>

<h1>Carbachol (Carbamycholine)</h1>

<p>
→ has both muscsarinic and nicotinic activity<br>
→ lacks the methyl group present in bethanechol<br>
→ but like bethanechol is an ester of carbamic acid and poor substrate for AChE.<br>
1.ACTION<br>
→ cardiovascular and GI systems<br>
<ul style='padding-left: 30pt'>
<li>cuz ganglion-stimulating activity  
<ul>
<li>and may first stimulate and then depress these systems</li>
</ul></li>
</ul>
→ release of epinephrine from the adrenal medulla by its nicotinic action<br>
→ locally instilled into the eye <br>
<ul style='padding-left: 30pt'>
<li>mimic the effect of ACh
<ul>
<li>causing miosis and a spasm of accomodtion</li>
</ul></li>
</ul>
2.THERAPEUTIC USE<br>
→ high potency <br>
→ receptor non selectivity  and long duration of action<br>
→ miotic agent to treat glaucoma<br>
<ul style='padding-left: 30pt'>
<li>onest of action for miosis is 10 to 20 min.</li>
</ul>
3.ADVERSE EFFECTS<br>
→ doses used ophthalmologically<br>
<ul style='padding-left: 30pt'>
<li>little or no side effects
<ul>
<li>due to the lack of system penetration</li>
</ul></li>
</ul>
</p>

<h1>PILOCARPINE</h1>

<p>
→ alkaloid is a tertiary amide and is stable hydrolysis by <a href="./AChE.html" title="AChE" class="page">AChE</a><br>
→ compared with ACh and its derivatives<br>
→ far less potent but is uncharged and will penatrate the CNS<br>
→ muscsarinic activity and used primarly in opthalmology
</p>

<p>
1.ACTION<br>
→ applied topically to the cornea<br>
<ul style='padding-left: 30pt'>
<li>produce rapid miosis and contraction of the ciliary muscle</li>
</ul>
[opposing the effects of atropine] <br>
→ one of the most potent stimulators of secretions (secretagogue)<br>
<ul style='padding-left: 30pt'>
<li>such as sweat,tears,saliva
<ul>
<li>but its used is limited because of it's lack of selectivity</li>
</ul></li>
</ul>
→ promoting salivation (xerostomia)<br>
<ul style='padding-left: 30pt'>
<li>Sjogerns syndrome
<ul>
<li>which characterized by dry mouth , and lack of tears
<ul>
<li>its treated with oral <i>pilocarpine tablets</i></li>
</ul></li>
</ul></li>
</ul>
2.THERAPEUTIC USE IN GLAUCOME<br>
→ is used to treat glaucoma<br>
<ul style='padding-left: 30pt'>
<li>lowering of intraocular pressure of both noarrow-angle and wide angle glaucoma</li>
</ul>
[carbonic anhydrase inhibitors(acetozolamide), β-adrenergic block (<i>timolol) </i>are effective to treating glaucoma but not in emergency for lowering intraocular pressure]<br>
→ miotic action of pilocarpine is also useful in reversing mydriasis due to atropine.<br>
→ actions occur within a few minutes ,lasts 4-8 hour<br>
3.ADVERSE EFFECTS<br>
→ can enter the brain and cause CNS distrubunces<br>
→ parasympathetic effects<br>
<ul style='padding-left: 30pt'>
<li>profuse sweating (diaphoresis), salivation.</li>
</ul>
[atropine parenteral at doses that can cross brain-blood-barrier ,is admin. to countact the toxicty of pilocarpine.
</p>

<h1>INDIRECT-ACTING CHOLINERGIC AGONISTS</h1>

<br>

<h1>ACETYLCHOLINESTERASE INHIBITORS (REVESIBLE)</h1>

<p>
<img src="./Pharmacology/pasted_image002.png"><br>
→AChE is an enzyme that specifically cleaves ACh to acetate and choline<br>
<ul style='padding-left: 30pt'>
<li>thus terminate its actions</li>
</ul>
→ located both pre and postsynaptically in the nerve terminal <br>
→ inhibitors of <a href="./AChE.html" title="AChE" class="page">AChE</a> inderectly provide cholinergic actions by prolonging the lifetime of ACh<br>
<ul style='padding-left: 30pt'>
<li>accumulation of ACh in the synaptic space</li>
</ul>
→ revesible <a href="./AChE.html" title="AChE" class="page">AChE</a> inhibitors can be broadly classified as short-acting or intermediate-acting agents.
</p>

<h1>EDROPHONIUM</h1>

<p>
→ prototype short acting <a href="./AChE.html" title="AChE" class="page">AChE</a> inhibitor<br>
<ul style='padding-left: 30pt'>
<li>bind revesibly to the active center of AChe preventing hydrolysis of Ach.</li>
</ul>
→ rapidly absorbed / short duration of action 10 to 20 min<br>
<ul style='padding-left: 30pt'>
<li>due to rapid elimination</li>
</ul>
→ is a quaternary amine and its action is limited in the periphery<br>
→ diagnosis of gravis<br>
<ul style='padding-left: 30pt'>
<li>causing the degradation making fewer receptors availalbe for interaciton</li>
</ul>
→ iv = rapid increase in muscle strenght<br>
→ excess of the drug may provoke cholinergic crisis (atropine is the antidote)<br>
→ may also used to assess cholinesterase inhibitor therapy <br>
<ul style='padding-left: 30pt'>
<li>for differentiating cholinergic and myasthenic crises.</li>
</ul>
</p>

<h1>PHYSOSTIGMINE</h1>

<p>
→is a nitrogenous carbamic acid ester found natuarly in plants and is a tertiary amine<br>
→ substrate for <a href="./AChE.html" title="AChE" class="page">AChE</a> and it forms a relatively stable cabamoylated intermediate with the enzyme<br>
<ul style='padding-left: 30pt'>
<li>which becomes revesibly inactivated</li>
</ul>
→ potentiation of cholinergic activity througout body<br>
1.ACTION<br>
→ stimulates not only the muscsarinic and nicotinic sites of the ANS<br>
→ nicotinic receptors of the NMJ<br>
→ 2 to 4 hours<br>
<ul style='padding-left: 30pt'>
<li>considered to be intermediate-acting-agent</li>
</ul>
→ enter and stimulate the cholinergic sites in the CNS<br>
2.THERAPEUTIC USES<br>
→ intestinal and bladder motility <br>
<ul style='padding-left: 30pt'>
<li>in atony </li>
</ul>
→ topically in the eye<br>
<ul style='padding-left: 30pt'>
<li>miosis and spasm of accomodation</li>
</ul>
→ treat glaucoma but pilocarpine is more active<br>
→ used in the treatment of overdoses of drugs with<br>
<ul style='padding-left: 30pt'>
<li>cholinergic action 	
<ul>
<li>atropine,phenothiazines,tricylic antidepressant</li>
</ul></li>
</ul>
3.ADVERSE EFFECTS<br>
→ convulsions,bracycardia,fall in cardiac output<br>
→ accumulation of ACh → paralysis of skeletal muscle.
</p>

<h1>NEOSTIGMINE</h1>

<p>
→ synthetic compound that is also carbamic acid ester<br>
<ul style='padding-left: 30pt'>
<li>revesibly inhibits AChe in a manner similar to physostigmine.</li>
</ul>
1.ACTIONS<br>
→ has a quaternary nitrogen <br>
<ul style='padding-left: 30pt'>
<li>is more polar </li>
<li>absorbed poorly from the GI</li>
<li>does not enter the CNS</li>
<li>effect on skeletal muscsle is greater that that of physostigmine
<ul>
<li>can stimulate contractility before it paralyze.</li>
</ul>
</li>
<li>intermediate duration of action 
<ul>
<li>usually 30 min to 2 hours</li>
</ul></li>
</ul>
2.THERAPEUTIC USE<br>
→ stimulate the bladder of GIT<br>
<ul style='padding-left: 30pt'>
<li>as an antidote for tubocurine  and other competative neuromuscular blocking agents.</li>
</ul>
→ used symptomatmically to treat myasthenia gravis<br>
→ neostigine and other <a href="./AChE.html" title="AChE" class="page">AChE</a> inhibitors<br>
<ul style='padding-left: 30pt'>
<li>preserve endogenous ACh</li>
<li>stimulate a greater numbe of ACh receptors at the muscle endplate.</li>
</ul>
3,ADVERSE EFFECTS<br>
→ Cholinergic stimulation<br>
<ul style='padding-left: 30pt'>
<li>salivation</li>
<li>flushing</li>
<li>↓ blood pressure</li>
<li>nausea</li>
<li>abdominal pain</li>
<li>diarrhea</li>
<li>bronchospams</li>
</ul>
</p>

<h1>PYRIDOSTIGMINE AND AMBENONIUM</h1>

<p>
→ cholinesterase inhibitor that are used <br>
<ul style='padding-left: 30pt'>
<li>in the chronic managment of myasthenia gravis</li>
</ul>
→ intermediate 3 to 6 and 4 to 8 hours respectively<br>
<ul style='padding-left: 30pt'>
<li>but longer than that of neostigmine.</li>
</ul>
→ adverse effects<br>
<ul style='padding-left: 30pt'>
<li>similar to those of neostigmine.</li>
</ul>
</p>

<h1>TARCINE,DONEPEZIL,RIVASTIGMINE AND GALANTAMINE</h1>

<p>
→anticholinesterases as possible remedies for the loss of congistive function<br>
→ <i>Tacrine</i><br>
<ul style='padding-left: 30pt'>
<li>was the first availalbe but replaced because of the hepatotoxicity </li>
</ul>
→ the others can delay the progression of Alzheimer disease<br>
<ul style='padding-left: 30pt'>
<li>none can stop the progression.</li>
</ul>
→ GIT distress is their primarly adverse effect
</p>

<h1>INDIRECT-ACTING CHOLINERGI AGONISTS</h1>

<br>

<h1>ANTICHOLINESTERASES (IRREVERSIBLE)</h1>

<p>
→ synthetic organophosphate compounds <br>
<ul style='padding-left: 30pt'>
<li>bind covalently to <a href="./AChE.html" title="AChE" class="page">AChE</a> 
<ul>
<li>as a result long-lasting increase in ACh at all sites where it is released</li>
</ul>
</li>
<li>many of these drugs are extremely toxic </li>
</ul>
</p>

<h1>Echothiophate</h1>

<p>
1.MECHANISM OF ACTION<br>
→ one of organophosphate that covalently bonds via its phosphate group to the serine OH group<br>
<ul style='padding-left: 30pt'>
<li>at the active site of <a href="./AChE.html" title="AChE" class="page">AChE</a></li>
</ul>
→ perma inactivated and restoration of <a href="./AChE.html" title="AChE" class="page">AChE</a> activity requires the synthesis of new enzymes molecules.<br>
<ul style='padding-left: 30pt'>
<li>following covalent modification of <a href="./AChE.html" title="AChE" class="page">AChE</a>
<ul>
<li>phosphorylated enzyme slowly release one of its ehtyl groups
<ul>
<li>loss of alkyl group which is called "agining"
<ul>
<li>makes imopssible for chemical reactivators 
<ul>
<li>such as <i>pralidoxime </i> to break the bond between the remaining drug and the enzyme</li>
</ul></li>
</ul></li>
</ul></li>
</ul></li>
</ul>
2.ACTIONS<br>
→ cholinergic stimulation<br>
<ul style='padding-left: 30pt'>
<li>paralyis of motor function and convulsion</li>
</ul>
→ produce intense miosis <br>
→ intraocullar pressure falls from the facilitatation of outlfow of aqueus humor.<br>
3.THERAPEUTIC USE<br>
→ chronic treatment of open-glaucoma [but its not the first line treatment]<br>
→ <br>
<img src="./Pharmacology/pasted_image005.png">
</p>

<br>

<h1>CHOLINERGIC ANTAGONIST (PARASYMPATOLYTICS)-(ANTICHOLINERGIC DRUGS)</h1>

<p>
<img src="./Pharmacology/pasted_image006.png">
</p>

<h1>OVERVIEW</h1>

<p>
→ selectively block muscarinic receptors of the parasympathetics nerves.<br>
<ul style='padding-left: 30pt'>
<li>bind to cholinoreceptor</li>
</ul>
→ second group is the "ganglionic blockers"<br>
<ul style='padding-left: 30pt'>
<li>show a preference for nicotinic receptors</li>
</ul>
→ thrid family of compounds<br>
<ul style='padding-left: 30pt'>
<li>neuromascular-blocking agents
<ul>
<li>interfere with tranmission of efferent impulses to skeletal muscle.</li>
</ul></li>
</ul>
→ used as relaxant adjuvants in anesthesia
</p>

<h1>ANTIMUSCARINIC AGENTS</h1>

<p>
<img src="./Pharmacology/pasted_image007.png"><br>
→ <i>ATROPINE and SCOPOLAMINE</i><br>
<ul style='padding-left: 30pt'>
<li>block muscsarinic receptors 
<ul>
<li>caausing inhibition of all muscarinic funcitons</li>
</ul>
</li>
<li>not blocking nicotinic receptors thats why are used more clinically than cholinergics agonists</li>
</ul>
→ some anthihistaminics and anti depressants also have antimuscarinic properties.
</p>

<h1>ATROPINE</h1>

<p>
→ tetriary amine belladona alkaloids<br>
<ul style='padding-left: 30pt'>
<li>high affinity for muscarinic receptors</li>
<li>binds competatively and prevent ACh from binding </li>
</ul>
→ acts centrally or peripherally<br>
<ul style='padding-left: 30pt'>
<li>actions last for 4 hours
<ul>
<li>except when applied topically in the eye [where the action may last for days]</li>
</ul></li>
</ul>
→ greatest inhibitory effects are on bronchial tissue and the secretion of sweat and saliva.<br>
1.ACTIONS<br>
a.eye<br>
→ block all cholinergic activity on the eye <br>
<ul style='padding-left: 30pt'>
<li>presistent mydriasis (dilation of the pupil)</li>
<li>unresponsivenss to light</li>
<li>cycloplegia</li>
</ul>
→ intraocular pressure may rise dangersly<br>
→ <i>Tropicamide</i><br>
<ul style='padding-left: 30pt'>
<li>or an α-adrenergic drugs
<ul>
<li><i>phenyllephrine </i>are generally favored for producing mydriasis.</li>
</ul></li>
</ul>
→ <br>
b.GI<br>
→ active isomer (I-hyosciamine)<br>
<ul style='padding-left: 30pt'>
<li>can be used as antispamspodic to ↓ activity of the GI tract</li>
<li>Atropine and Scopolamine are the most potent</li>
</ul>
→ although gastric motility is ↓ <br>
<ul style='padding-left: 30pt'>
<li>not effective promoting healing of peptic ulcer</li>
</ul>
→ doses of atropine that reduce spams also<br>
<ul style='padding-left: 30pt'>
<li>reduce saliva secretion</li>
<li>ocular accomodetion</li>
<li>micturirion (urination)</li>
</ul>
c.urinary system<br>
→ reduce hypersmolarity states of the urinary bladder<br>
→ enuresis among children<br>
d.cardiovasular<br>
→ produce divergent effects on the cvs<br>
→ ↓ cardiac rate (bradycardia)<br>
→ higher doses <br>
<ul style='padding-left: 30pt'>
<li>cardiac rate ↑ modestly.</li>
</ul>
<ul>
<li>1 mg of atropine [which is the higher doses that ordiarily given]</li>
</ul>
e.Secretons<br>
→ blcoks the salivery glands<br>
<ul style='padding-left: 30pt'>
<li>drying effect on the oral mucous(xerostomia)
<ul>
<li>also sweat and lacrimal glands
<ul>
<li>elevated body temperature</li>
</ul></li>
</ul></li>
</ul>
2.THERAPEUTIC USE<br>
a.opthalmic<br>
→ mydriatic and cycloplegic effect<br>
→ <i>phenylephrine <u> or </u></i> similar a-adrenergic drugs<br>
<ul style='padding-left: 30pt'>
<li>prefered for pupillary dilation [due to prolonged effect of the drug]</li>
</ul>
→ shorter acting antimuscarinic <br>
<ul style='padding-left: 30pt'>
<li><i>cyclopentolate and tropicamide</i></li>
</ul>
→ can induce acute attack of eye pain due to sudden increases in eye pressure.<br>
d.antispasmodic<br>
→ relax GI tract and bladder<br>
c.antidote for cholinergic agonist<br>
→ cholinesterase inhibitor inscecticides<br>
<ul style='padding-left: 30pt'>
<li>and some types of mush poisoning</li>
</ul>
→ blocks the effects of excess ACh <br>
<ul style='padding-left: 30pt'>
<li>derived from the action of inhibitors of <a href="./AChE.html" title="AChE" class="page">AChE</a> such as <i>physostigmine.</i></li>
</ul>
3.PHARMACOKIENTICS<br>
→ readily absorbed<br>
→ partialy metabolized by the liver<br>
→ eliminated primarly by the urine<br>
→ half-life about 4 hours<br>
4.ADVERSE EFFECTS<br>
→ dry mouth<br>
<ul style='padding-left: 30pt'>
<li>blurred vision</li>
<li>sandy eyes</li>
<li>tachycardia</li>
<li>urinary retention</li>
<li>constipation</li>
<li>restlesness</li>
<li>confusion</li>
<li>hallucination</li>
<li>dellirum          ⇒ which may result to depression</li>
</ul>
</p>

<h1>SCOPOLAMINE</h1>

<p>
→ another tertiary amine plant alkaloid<br>
→ producec pripheral effects similar to those of atropine<br>
→ greater action on the CNS<br>
<ul style='padding-left: 30pt'>
<li>longer duration of action in comparsion to those of atropine</li>
</ul>
1.ACTIONS<br>
→ most effective anti-motin sickness drug available<br>
→ unsual effect of blocking short-term memory<br>
→ produce sedation (in contrast to atropine)<br>
<ul style='padding-left: 30pt'>
<li>but higher doses
<ul>
<li>can produce excitement instead.</li>
</ul></li>
</ul>
→ may produce euphoria and often is abused.<br>
2.THERAPEUTIC USES<br>
→ although similar to atropine<br>
→ motion sickness<br>
<ul style='padding-left: 30pt'>
<li>prophylacticaly </li>
</ul>
3.PHARMACOKINETICS AND ADVERSE EFFECTS<br>
→ similar to those of atropine
</p>

<h1>IPRATROPIUM AND TIOTROPIUM</h1>

<p>
→inhaled<br>
→ quaternary derivatives of atropine<br>
→ bronchodilators for maintenance treatment of brochospams (assosciated with COPD)<br>
<ul style='padding-left: 30pt'>
<li>chronic bronchitis or edema</li>
</ul>
→ do not enter the systemic circulation or the CNS<br>
<ul style='padding-left: 30pt'>
<li>isolating their effects in the pulmonary systeme</li>
</ul>
→ Tiotropium<br>
<ul style='padding-left: 30pt'>
<li>admin. orally </li>
<li>major adv over ipratropium which requires dosing for four times daily</li>
</ul>
</p>

<h1>TROPICAMIDE AND CYCLOPENTOLATE</h1>

<p>
→ used similary to atropine as ophthalmic solution for<br>
<ul style='padding-left: 30pt'>
<li>mydriasis and cylcoplegia</li>
</ul>
→ duration of action is shorten than that of atropine<br>
→ tropicamide<br>
<ul style='padding-left: 30pt'>
<li>produce mydriasis for  6 hours </li>
</ul>
→ cyclopentolate	<br>
<ul style='padding-left: 30pt'>
<li>producecs mydriasis for 24 hours</li>
</ul>
</p>

<h1>BEZTRTROPINE AND TRIHEXYPHENIDYL</h1>

<p>
→ mostly centrally acting antimuscarinic agents<br>
<ul style='padding-left: 30pt'>
<li>used for years in the treatment of Parkinson diseae</li>
</ul>
→ levodopa/carbidopa replaced their use
</p>

<h1>DARIFERON , FESOTERODINE , OXYBUTYNIN , SOLIFENACIN , TOLTERODINE, TRISPIUM CHLORIDE</h1>

<p>
→ synthetic atropine-like drugs<br>
<ul style='padding-left: 30pt'>
<li>treat overactive urinary bladder diseae
<ul>
<li>by blocking msucarinic receptors in the bladder</li>
</ul>
</li>
<li>intravesicular pressure is lowered 
<ul>
<li>bladder capacity is ↑ </li>
<li>blaader contranction ↓ </li>
</ul></li>
</ul>
→ side effects of these agents<br>
<ul style='padding-left: 30pt'>
<li>dry mouth</li>
<li>constipation</li>
<li>blurred vision</li>
</ul>
→ Oxybutynin<br>
<ul style='padding-left: 30pt'>
<li>is availabne as transdermal patch</li>
<li><img src="./Pharmacology/pasted_image008.png"></li>
</ul>
</p>

<h1>GANGLIONIC BLOCKERS</h1>

<p>
→ act on nicotinic receptor <br>
<ul style='padding-left: 30pt'>
<li>of both para and sympathetic autonomic ganglia</li>
</ul>
→ some also block ion channels<br>
→ show no selectivity toward the para or sympathetic ganglia<br>
<ul style='padding-left: 30pt'>
<li>and not effective as neuromuscsular antagonist</li>
</ul>
→ block the entire output of the autonomic nervous system<br>
<ul style='padding-left: 30pt'>
<li>except for nicotine
<ul>
<li>the other drugs
<ul>
<li>are nondepolarizing,competative antagonist.</li>
</ul></li>
</ul>
</li>
<li>in general leads to vasodilation
<ul>
<li>will also produce atony of the bladder and GIT</li>
</ul></li>
</ul>
→ rarely used therapeutically but often serve as a tool in experimental pharmacology
</p>

<h1>Nicotine</h1>

<p>
→ poison with many undesirable effects<br>
→ depolarize autonomic ganglia<br>
<ul style='padding-left: 30pt'>
<li>first stimulate and then paraylis of all ganglia</li>
</ul>
→ ↑ release of neurotranmitter <br>
<ul style='padding-left: 30pt'>
<li>effect both para and sympathetic ganglia</li>
</ul>
→ ↑ release of dopamine and norepienphrine → pleasure / appetite supression<br>
→ ↑ blood pressure and ↑ cardiac rate<br>
→ ↑ peristalis and secration<br>
→ higher doses <br>
<ul style='padding-left: 30pt'>
<li>blood pressure ↓  [because of ganglionic blockage]</li>
<li>GIT and bladder muscularate caeses</li>
</ul>
</p>

<h1>Mecamylamine</h1>

<p>
→ produce competative nicotinic blockage of the ganglia<br>
→ 
</p>

<h1>NEUROMUSCULAR BLOCKING DRUGS</h1>

<p>
→ blcok cholinergic transmission <br>
<ul style='padding-left: 30pt'>
<li>between motor nerve andings </li>
<li>and nicotinic receptors 
<ul>
<li>on the endplate of skeletal muscsle</li>
</ul></li>
</ul>
→ are structually analogs of ACh<br>
<ul style='padding-left: 30pt'>
<li>and they act either 
<ul>
<li>antagonist(nondepolarizing type) or</li>
<li>agonist (depolarizing type) at the receptor of the endplate of the NMJ</li>
</ul></li>
</ul>
→ useful during surgery<br>
<ul style='padding-left: 30pt'>
<li>producing complete muscule relaxation</li>
</ul>
→ used in orthopedic surgery and trachel intubation as well<br>
→ second group of muscsle relaxants and central muscle relaxants<br>
<ul style='padding-left: 30pt'>
<li>are used to control spastic muscle tone
<ul>
<li><i>Diazepam </i>which binds ti GABA </li>
<li><i>Dantrolene </i>which act directly on muscles 
<ul>
<li>by interfereing with the release of calcium from the sarcoplasmic recticulum</li>
</ul>
</li>
<li><i>Baclofen acts at GABA receptors in the CNS</i></li>
</ul></li>
</ul>
</p>

<h1>Nondepolarizing (competative)blcokers</h1>

<p>
→ first drug blocking the skeletal NMJ was <i>Curare</i><br>
→ <i>Tubocuranine </i><br>
<ul style='padding-left: 30pt'>
<li>purifed and introduced into clinical practise in early 40's
<ul>
<li>but largerly replaced by other agents</li>
</ul></li>
</ul>
→ neuromascular blocking agents have increased safety in anesthesia
</p>

<br>


	</div>

	<br />

	<div class='page-footer'>

			<b>Attachments:</b>
			<table>

			<tr><td><a href='./Pharmacology/pasted_image.png'>pasted_image.png</a></td><td>&nbsp;</td><td>155kb</td></tr>


			<tr><td><a href='./Pharmacology/pasted_image001.png'>pasted_image001.png</a></td><td>&nbsp;</td><td>159kb</td></tr>


			<tr><td><a href='./Pharmacology/pasted_image002.png'>pasted_image002.png</a></td><td>&nbsp;</td><td>53.4kb</td></tr>


			<tr><td><a href='./Pharmacology/pasted_image003.png'>pasted_image003.png</a></td><td>&nbsp;</td><td>61.1kb</td></tr>


			<tr><td><a href='./Pharmacology/pasted_image004.png'>pasted_image004.png</a></td><td>&nbsp;</td><td>86.2kb</td></tr>


			<tr><td><a href='./Pharmacology/pasted_image005.png'>pasted_image005.png</a></td><td>&nbsp;</td><td>186kb</td></tr>


			<tr><td><a href='./Pharmacology/pasted_image006.png'>pasted_image006.png</a></td><td>&nbsp;</td><td>117kb</td></tr>


			<tr><td><a href='./Pharmacology/pasted_image007.png'>pasted_image007.png</a></td><td>&nbsp;</td><td>224kb</td></tr>


			<tr><td><a href='./Pharmacology/pasted_image008.png'>pasted_image008.png</a></td><td>&nbsp;</td><td>65.9kb</td></tr>

			</table>
	</div>

	

</div>

</body>
</html>
